Living Cell Technologies : Appendix 4C Quarterly Cash Flow Report 31 December 2018

Living Cell Technologies Limited

ACN:	104 028 042
ASX:	LCT
OTCQX:	LVCLY

ASX ANNOUNCEMENT

Appendix 4C Quarterly Cash Flow Report 31 December 2018

Sydney, Australia & Auckland, New Zealand, 30 January 2019 - Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 December 2018. The Appendix 4C is attached. The company ended the quarter with a cash balance of $5,422,314 compared to $6,196,075 in the previous quarter.

Net operating cash flow in the quarter was $(805,741) compared to $(718,087) in the previous quarter. Receipts from grants and tax incentives were $99,954 (previous quarter $205,420).

Operating payments were $952,060 compared to $1,000,644 in the previous quarter. Costs were incurred for continued monitoring and analysis of data in the NTCELL in Parkinson's disease studies, corporate costs associated with the Annual General Meeting in November and new product pilot studies.

Efficacy data from the Phase IIb NTCELL clinical study 2 years after implantation should be complete in all the treatment groups and available in May 2019.

- Ends -

For further information:www.lctglobal.com

At the Company: Ken Taylor Chief Executive Mobile: [phone]

Media Contact: Rachael Joel Botica Butler Raudon Partners Tel: [phone] Mobile: [phone]

About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

LCT's lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After implantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

The Phase I/IIa clinical trial of NTCELL for the treatment of Parkinson's disease, in New Zealand, met the primary endpoint of safety and halted the progression of the disease two and a half years after implant. Results from this trial were used to design a larger Phase IIb trial to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson's disease patient sub group. This trial commenced in March 2016. At 26 weeks post implant, there was no statistically significant difference between the group who received NTCELL and the patients who had the sham surgery, as measured by the change in the Unified Parkinson's Disease Rating Scale (UPDRS Part III in the off state). At one year, efficacy data shows a statistically significant improvement in the patients that received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery, as measured by the change in the Unified Parkinson's Disease Rating Scale (UPDRS Part III in the off state). Post implant results of this trial will continue to be monitored in accordance with the study extension protocol.

In addition to Parkinson's disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington's, Alzheimer's and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

LCT's proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT has initiated a collaboration with Sir Richard Faull, Centre for Brain Research, and Professor Margaret Brimble, The University of Auckland, to identify and synthesize a pericyte protective agent that may have potential therapeutic benefit in neurodegenerative diseases. LCT is also doing due diligence on other product opportunities in the field of translational neuroscience.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information, visitwww.lctglobal.com or follow @lctglobal on Twitter.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Appendix 4C

+Rule 4.7B

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity: LIVING CELLTECHNOLOGIES LIMITEDABN

14 104 028 042

Quarter ended ("current quarter")

31 December 2018

Consolidated statement of cash flows	Current quarter $A	Year to date (6 months) $A
1. Cash flows from operating activities 1.1 Receipts from customers 1.2 Payments for (a) research and development (b) product manufacturing and operating costs (c) advertising and marketing (d) leased assets (e) staff costs (f) administration and corporate costs 1.3 Dividends received (see note 3) 1.4 Interest received 1.5 Interest and other costs of finance paid 1.6 Income taxes paid 1.7 Government grants and tax incentives 1.8 Other (provide details if material) 1.9 Net cash from / (used in) operating activities	29,900 (283,026) - (8,772) (50,106) (239,737) (370,419) - 16,465 - - 99,954 -	83,304 (712,873) - (16,116) (113,748) (509,809) (600,164) - 40,198 - - 305,374 -
	(805,741)	(1,523,834)

2.	Cash flows from investing activities
2.1	Payments to acquire:
(a) property, plant and equipment	(10,322)	(10,322)
(b) businesses (see item 10)	-	-
(c) investments	-	-

Page 1

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows	Current quarter $A	Year to date (6 months) $A
(d) intellectual property (e) other non-current assets 2.2 Proceeds from disposal of: (a) property, plant and equipment (b) businesses (see item 10) (c) investments (d) intellectual property (e) other non-current assets 2.3 Cash flows from loans to other entities 2.4 Dividends received (see note 3) 2.5 Other (provide details if material) 2.6 Net cash from / (used in) investing activities	- - - - - - - - - -	- - - - - - - - - -
	(10,322)	(10,322)

3. Cash flows from financing activities 3.1 Proceeds from issues of shares 3.2 Proceeds from issue of convertible notes 3.3 Proceeds from exercise of share options 3.4 Transaction costs related to issues of shares, convertible notes or options 3.5 Proceeds from borrowings 3.6 Repayment of borrowings 3.7 Transaction costs related to loans and borrowings 3.8 Dividends paid 3.9 Other (provide details if material) 3.10 Net cash from / (used in) financing activities	- - - - - - - - -	- - - - - - - - -
	-	-

• 4. Net increase / (decrease) in cash and cash equivalents for the period

• 4.1 Cash and cash equivalents at beginning ofquarter/year to date

• 4.2 Net cash from / (used in) operating activities (item 1.9 above)

• 4.3 Net cash from / (used in) investing activities (item 2.6 above)

• 4.4 Net cash from / (used in) financing activities (item 3.10 above)

6,196,075 (805,741)

6,861,663 (1,523,834)

(10,322)

(10,322)

-

-

Page 2

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows	Current quarter $A	Year to date (6 months) $A
4.5 Effect of movement in exchange rates on cash held 4.6 Cash and cash equivalents at end of quarter	42,302	94,807
	5,422,314	5,422,314

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A	Previous quarter $A
5.1 Bank balances 5.2 Call deposits 5.3 Bank overdrafts 5.4 Other (provide details) 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	540,526 4,881,788 - -	996,983 5,199,092 - -
	5,422,314	6,196,075

• 6. Payments to directors of the entity and their associates

• 6.1 Aggregate amount of payments to these parties included in item 1.2

• 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

  Current quarter

  $A

• 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

56,667 -

• 7. Payments to related entities of the entity and their associates

• 7.1 Aggregate amount of payments to these parties included in item 1.2

• 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

  Current quarter

  $A

• 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

- -

+ See chapter 19 for defined terms

1 September 2016

Page 3